On February 10, Indian pharmaceutical giant Aurobindo Pharma said that its consolidated net profit for the October–December quarter of the current fiscal year increased by 90.6 percent year over year to Rs 936.2 crore.
For the same time last year, the company reported a profit of Rs 491.2 crore.
Operating revenue in Q3 FY24 totaled Rs 7,351.7 crore, a 14.7 percent increase over Q2 figures of Rs 6,407 crore from the previous year.
Earnings before interest, taxes, depreciation, and amortization (EBITDA) for the company increased to Rs 1,601 crore from Rs 954.4 crore in the same period last year.
Revenues from formulations increased by 1.6% YoY to Euro 193 million in Europe and by 28.9% YoY to $45.1 crore in the US.
In Q3FY24, Specialty & Injectables revenue in the US amounted to about $11.2 crore, or 25% of total US revenue. Proforma revenue for Global Specialty & Injectables was around $15 crore. In Q3FY24, the business submitted seven ANDAs to the USFDA. Throughout the quarter, the business released 21 products, four of which were specialty and injectable goods. Additionally, 16 ANDAs, seven of which were specialty and injectable products, were approved.
The ARV (Anti Retro Viral) company reported $22 million in revenue, or 2.4% of total revenue.
